David Azorsa
Associate Professor
Clinical Translational Research Division
Translational Genomics Research Institute
United States of America
Biography
Dr. Azorsa received his Ph.D. from the Department of Pharmacology and Molecular Sciences at the Johns Hopkins University School of Medicine in Baltimore, MD. He completed his post-doctoral training at the INSERM U.311 in Strasbourg, France and the Cancer Genetics Branch of the National Human Genome Research Institute in Bethesda, MD. Dr. Azorsa joined the Cancer Drug Development Laboratory at TGen in 2003 where he developed the HT-RNAi platform for functional genomics. He is currently using HT-RNAi in the Biological Therapeutics Laboratory, which he currently heads within the Clinical Translational Research Division.
Research Interest
Novel biological therapeutic agents in the form of monoclonal antibodies (mAbs) and short-interfering RNA (siRNA), breast cancer, ovarian cancer, pancreatic cancer, and pediatric sarcomas.
Publications
-
Amplification and overexpression of vinculin are associated with increased tumour cell proliferation and progression in advanced prostate cancer J Pathol Epub ahead of print 2010
-
EphB2 expression across 138 human tumor types in a tissue microarray: high levels of expression in gastrointestinal cancers. Clinical Cancer Research Sep; 15;11(18):6450-8. 2005
-
Functional evidence implicating S100P in prostate cancer progression Int J Cancer, 123(2):330-339 2008
-
Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid restricted kinase, GRK6. Blood Feb;115:1594-604 2010
-
Intersex-like (IXL) Is a Cell Survival Regulator in Pancreatic Cancer with 19q13 Amplification Cancer Research, Vol 5 No 67:1943-1949. 2007
